Companies / PAR

PARADIGM BIOPHARMACEUTICALS LIMITED..

ASX:PARPharmaceuticals, Biotechnology & Life Sciences
594.3M shares on issueASX (delayed) · as of 28 July 2026$0.17price · delayed$98.1Mmarket cap · indicative
D
Dilution grade

Share count grew 70% in 24 months; runway 2–4 quarters; 5 cash raises in 24 months

Cash runway2.2 quarters of funding
Share-count growth (24m)69.9%
Raise cadence (24m)5 cash raises
Options & rights overhang43.7% of shares
In-the-money supply0.0% of shares
Pending proposed issuesnone

PARADIGM BIOPHARMACEUTICALS LIMITED.. had 594M ordinary shares as of July 2026, an increase of 69.9% between May 2024 and July 2026. The company raised capital five times in that period for total disclosed proceeds of A$55.7M, most recently a Placement and Share Purchase Plan that raised A$21.4M in April 2026. Options and rights could convert into 260M new shares, equal to 43.7% of the current share count, with the nearest expiry in December 2026 and 0% of current shares in the money. At the March 2026 quarter the company reported A$23.8M in cash, covering 2.2 quarters. No proposed securities issues (Appendix 3B) are pending.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
43.7%
Max option dilution
0.0%
ITM option dilution
1
Raises · last 12 months
2.2 qtrs
Cash cover · 2–4 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 594.3M per ASX (delayed) (28 July 2026).
400.8M471.9M542.9MDec 24Sept 25July 26Cash raise · 27 Apr 2026Cash raise · 1 July 2025Cash raise · 3 Feb 2025Cash raise · 30 Jan 2025Cash raise · 4 Dec 2024

Cash runway

2.2 qtrs
Two to four quarters of funding at the recent spend rate.
$23.8M available cash at quarter ended 31 Mar 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 31 Mar 2026.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
26 July 20263H · cancellationPAR : ORDINARY FULLY PAID594.0MAppendix 3H
17 July 20262A · quoted issuePAR : ORDINARY FULLY PAID594.3MAppendix 2A
13 July 20263G · unquotedORDINARY FULLY PAID584.8MAppendix 3G
29 June 20263H · cancellationPAR : ORDINARY FULLY PAID584.8MAppendix 3H
29 June 20263H · cancellationPAR : ORDINARY FULLY PAID586.6MAppendix 3H
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

5 cash raises in the last 24 months · 1 in the last 12 months

$21.4M
Placement and Share Purchase Plan
27 Apr 2026 COMPLETE
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

43.7%
Total overhang · of current shares
0.0%
In the money · at current price
259.9M
Potential new shares
Dec 2026
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

DateDirectorTypeSharesOptionsValueSource
29 June 2026Paul RennieSell———3Y notice
18 June 2026Matthew FryOther1.6M176k—3Y notice
18 June 2026Paul RennieOther—176k—3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

26 July 2026Notification of cessation of securities - PAR
21 July 2026$PParadigm Receives $5.75m R&D Tax Incentive Refund
17 July 2026Application for quotation of securities - PAR
13 July 2026Notice under Section 708A
13 July 2026Notification regarding unquoted securities - PAR
13 July 2026$PDrawdown of Tranche 4 under the Convertible Note Facility
1 July 2026Change of Director's Interest Notice
29 June 2026Notification of cessation of securities - PAR
29 June 2026Notification of cessation of securities - PAR
18 June 2026Change of Director's Interest Notice
18 June 2026Change of Director's Interest Notice
18 June 2026Application for quotation of securities - PAR
17 June 2026Listing of Options - Top 20 Holders and Distribution Reports
17 June 2026Application for quotation of securities - PAR
14 June 2026$PPAR Completes Enrolment in Pivotal Phase 3
11 June 2026Options Prospectus
11 June 2026Results of Meeting
5 June 2026Change of Director's Interest Notice
5 June 2026Change of Director's Interest Notice
3 June 2026Ceasing to be a substantial holder

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.